glp-1 nejm In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron, an oral glucagon-like peptide-1 receptor agonist, led to significant mean body-weight reductions in patients with obesity, as compared with placebo. Full In the ATTAIN-1 phase 3,

GLP-1 receptor agonists were designed for weight management and diabetes, but emerging evidence suggests potential intersections with chronic pain pathways

This article explores current clinical evidence, provider decision-making frameworks, and how genetic insights may inform a personalized conversation with your healthcare

Several clients have reported itchy scalps, and it's a pattern that's been noticed

A National Institutes of Health (NIH)-funded study has found that an emerging class of GLP-1 weight loss drugs suppress eating for pleasure, or hedonic feeding, in mice by modulating a reward circuit deep within the brain

In addition to lifting dead cells, this formulation tones skin, refines pores, and soothes irritation